BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Allegro Diagnostics Completes Patient Enrollment in 1,320-Patient AEGIS II Study of BronchoGen™ Genomic Test for Improved Detection of Lung Cancer


7/24/2012 9:56:18 AM

MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced the completion of enrollment in the 1,320-patient AEGIS II (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trial, which is evaluating the diagnostic ability of the BronchoGen™ genomic test used in conjunction with bronchoscopy to detect early signs of lung cancer compared to the ability of bronchoscopy alone. BronchoGen is Allegro Diagnostics’ lead genomic test, and it is built upon the Company’s molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Data from the AEGIS II study are expected in mid-2013.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->